Clinical Trial Confirms Mood Benefits of Relora

August 26, 2013

Test subjects enjoyed “significant” improvement from Next Pharmaceuticals ingredient versus placebo.

A new clinical trial on Relora, a proprietary blend of Magnolia officinalis and Phellodendron amurense from Next Pharmaceuticals (Salinas, CA), has found the ingredient to have a beneficial effect on mood and other psychological states without any reported adverse effects.

Fifty-six study subjects who were experiencing moderate levels of perceived psychological stress were dosed with either Relora or a placebo twice a day for four weeks, during which time saliva samples were collected for cortisol testing. Test subjects also completed a questionnaire to quantify their respective moods on the first and last day of the study.

According to the data collected, researchers concluded that the daily use of Relora reduced cortisol exposure and perceived stress while improving a variety of mood parameters – most significantly, anger was reduced by 42%, and fatigue was reduced by 31%.

What’s more, overall stress was reduced by 11%, tension was reduced by 13%, depression was reduced by 20%, and confusion was reduced by 27%. Salivary cortisol exposure decreased by 18%.

The study was conducted by Supplement Watch/GLH Nutrition and accepted for publication in the Journal of the International Society of Sports Nutrition (2013, 10:37).